Discover investment opportunities in Best Stocks Under $1 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Stocks Under $1 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Stocks Under $1 using our Smart AI Filter.
5 stocks found for "Best Stocks Under $1"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.36 | ±100.0% | -0.2 | 0.00% | |||
1.56 | ±83.0% | -16.0 | 0.00% | |||
1.18 | ±100.0% | -1.1 | 0.00% | |||
0.82 | ±100.0% | -0.3 | 0.00% | |||
1.24 | ±72.2% | -6.2 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: How has Advaxis, Inc. (ADXS) stock historically performed during economic downturns?
A: Some investors note that Advaxis, Inc. (ADXS), a biotechnology company, generally exhibits high volatility, a common trait in biotech stocks, which can result in significant price fluctuations during economic downturns. Historical performance should be analyzed in the context of clinical trial results and funding availability.
Q: What sector does Tonix Pharmaceuticals Holding Corp. (TNXP) belong to, and what are its growth prospects?
A: Tonix Pharmaceuticals Holding Corp. (TNXP) operates in the biotechnology sector, focusing on neurological conditions. Growth prospects depend on pipeline developments, clinical trial successes, and regulatory approvals. Investors interested in innovative therapeutics might find this appealing but should be wary of high volatility.
Q: Are there any potential competitive advantages for AIkido Pharma Inc. (SONN)?
A: AIkido Pharma Inc. (SONN) focuses on early-stage biotechnology research. Its potential competitive advantages include proprietary technologies and collaborations with research institutions. Success often hinges on innovation and regulatory approval, offering high reward with significant risk.
Q: What are the primary risks associated with investing in Reed's, Inc. (REED)?
A: Reed's, Inc. (REED) operates in the consumer goods sector, specializing in beverages. Key risks include fluctuating consumer preferences, raw material costs, and distribution challenges. As a small-cap stock, it may also experience high volatility and limited liquidity.
Q: How does Naked Brand Group Limited (NAKD) align with ESG investment criteria?
A: Naked Brand Group Limited (NAKD) operates in the apparel sector with a focus on intimate garments. Its alignment with ESG criteria depends on its sustainability practices, supply chain transparency, and labor policies. Investors should research company reports for detailed ESG performance.
Q: What is the income potential for investors in SeaChange International, Inc. (SEAC)?
A: SeaChange International, Inc. (SEAC) provides digital video technology solutions. The income potential derives primarily from capital gains as opposed to dividends. Investors may see value in the company's technological advancements, although revenue growth and competition must be considered.
Advaxis Inc (NASDAQ: ADXS) has initiated a Phase 1 study evaluating ADXS-504 in patients with recurrent prostate cancer. The study, being conducted at Columbia University Irving Medical Center, is the first clinical evaluation of ADXS-504, Advaxis' off-the-shelf neoantigen immunotherapy drug candidate for early prostate cancer.
Read more